Cardiovascular Business January 2, 2025
Transforming cardiac prevention screenings
The TRANSFORM trial will enroll more than 7,000 patients classified as moderate to high risk for cardiovascular events. Participants will be randomized into two groups. The control group will receive guideline-based care, while the investigational group will undergo CCTA scans at baseline and two years later. These scans, enhanced by AI assessment and detailed quantification of the various types of coronary plaques, will classify coronary plaque into stages of severity, dictating the intensity of medical intervention.
“So if they’ve got stage zero plaque, meaning they don’t have any coronary plaque, they will get treated according to guidelines. So if the LDL cholesterol is super high, it’ll still get treated. For example, on the other hand, if...
Today's Sponsors
Today's Sponsor